Related scientific articles (all)

Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.

Authors : Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L
Year : 2017
Journal : Immune Netw
Volume : 17
Pages : 89-102

Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: a longitudinal cohort study.

Authors : Libert Y, Borghgraef C, Beguin Y, Delvaux N, Devos M, Doyen C, Dubruille S, Etienne AM, Liénard A, Merckaert I, Reynaert C, Slachmuylder JL, Straetmans N, Van Den Neste E, Bron D, Razavi D
Year : 2017
Journal : Psychooncology
Volume : 26(12)
Pages : 2086-2093

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors : Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P
Year : 2017
Journal : N Engl J Med
Volume : 376
Pages : 1311-1320

Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.

Authors : Maertens J, Graux C, Breems D, Havelange V, Wittnebel S, Strens D, Hoefkens C
Year : 2017
Journal : Acta Clin Belg
Volume : 72(6)
Pages : 429-433

Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.

Authors : Kourie HR, Ameye L, Paesmans M, Bron D
Year : 2017
Journal : Br J Haematol
Volume : 179 (5)
Pages : 846-848

Data on HO-1 and CD200 protein secretion during T-cells and mesenchymal stromal cells co-cultures.

Authors : Fayyad-Kazan M, Fayyad-Kazan H, Merimi M, Meuleman N, Bron D, Lagneaux L, Najar M
Year : 2017
Journal : Data Brief
Volume : 11
Pages : 442-445

Repression of Human T-lymphotropic virus type 1 Long Terminal Repeat sense transcription by Sp1 recruitment to novel Sp1 binding sites.

Authors : Fauquenoy S, Robette G, Kula A, Vanhulle C, Bouchat S, Delacourt N, Rodari A, Marban C, Schwartz C, Burny A, Rohr O, Van Driessche B, Van Lint C
Year : 2017
Journal : Sci Rep
Volume : 7
Pages : 43221

Results from the Belgian mantle cell lymphoma registry.

Authors : Vergote V, Janssens A, André M, Bonnet C, Van Hende V, Van Den Neste E, Van Eygen K, Maerevoet M, Pranger D, Schroyens W, Debussche S, Maertens V, Beel K, Lemmens J, Caron C, Delrieu V, Van Den Broeck I, Vanstraelen G, Jacquy C, Schauvlieghe L, De Samblanx H, Madoe V, Meers S, Boulet D, Verhoef G, van Hoof A
Year : 2017
Journal : Acta Clin Belg
Volume : 72(3)
Pages : 172-178

New therapeutic approaches in cutaneous T-cell lymphomas

Authors : Bron D, Springael C, Maerevoet M, De Vicq M, Kolivras A
Year : 2017
Journal : Belgian J Hematology
Volume : 8
Pages : 102-6

Study of the microRNA expression profile of foreskin derived mesenchymal stromal cells following inflammation priming.

Authors : Fayyad-Kazan H, Fayyad-Kazan M, Badran B, Bron D, Lagneaux L, Najar M
Year : 2017
Journal : J Transl Med
Volume : 15
Pages : 10

A phase III randomized trial comparing Inolimomab vs. usual care in steroid-resistant acute GVHD.

Authors : Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P, Medeghri Z, Lehert P, Lai C, Corn T, Vernant JP
Year : 2017
Journal : Blood
Volume : 129(5)
Pages : 643-9

Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.

Authors : Chaput F, Amer R, Baglivo E, Touitou V, Kozyreff A, Bron D, Bodaghi B, LeHoang P, Bergstrom C, Grossniklaus HE, Chan CC, Peer J, Caspers LE
Year : 2017
Journal : Ocul Immunol Inflamm
Volume : 25(5)
Pages : 639-648

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Authors : Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S
Year : 2017
Journal : Lancet Oncol
Volume : 18(1)
Pages : 52-62

Reply to M. Lambertini et al.

Authors : Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Year : 2017
Journal : J Clin Oncol
Volume : 35(7)
Pages : 805-6

Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: an exploratory study.

Authors : Libert Y, Borghgraef C, Beguin Y, Delvaux N, Devos M, Doyen C, Dubruille S, Etienne AM, Liénard A, Merckaert I, Reynaert C, Slachmuylder JL, Straetmans N, Neste EV, Bron D, Razavi D
Year : 2017
Journal : Psychooncology
Volume : 26(1)
Pages : 118-24

Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined Phase I/II results of the EORTC

Authors : Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F
Year : 2017
Journal : Haematologica
Volume : 102(2)
Pages : e47-51

Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA.

Authors : Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, Gomes Da Silva M, Maerevoet M, Laurent C, Coiffier B, Salles G, Traverse-Glehen A
Year : 2017
Journal : Haematologica
Volume : 102(1)
Pages : 150-9

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Authors : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Year : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pages : 6411-6420

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Authors : Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart-Gebhart M, Von Minckwitz G, Baselga J, Loi S
Year : 2017
Journal : Eur J Cancer
Volume : 85
Pages : 133-145

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Car

Authors : Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, OToole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB
Year : 2017
Journal : Adv Anat Pathol
Volume : 24
Pages : 311-335